Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Cell Therapy
A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology – Labiotech.eu (blog)
Posted: March 8, 2017 at 6:41 am
CAR-T has been hailed as a cure for cancer, butwhat really is this miraculous technology and what can we actually expect when it reaches the market?
The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the success of the first checkpoint inhibitorson the market, many are turning their attention to CAR-T therapy,the next big cancer therapy to hit the market.
But is CAR-T therapy really a cure for cancer, as many seem to believe? Can the technology meet such high expectations? Are the recent deaths in clinical trials a sign that CAR-T is not ready for commercialization? What will the future bring?
To answer some of the most burning questions, Italked with some of the leaders in this field to draw an overview of the current state of the field.
CAR therapy is at the same time cell therapy, gene therapy, and immunotherapy.It represents a radical departure from all forms of medicine in existence until now, Michel Sadelain, co-founder of Juno Therapeutics, told The Scientist.
A CAR-T therapy consists in the infusion of engineered T-cells that express a Chimeric Antigen Receptor (CAR) on their cell membrane. This receptor counts with an externaltarget-binding domain designed to recognize a specific tumor antigen and an internalactivation domain responsible for activating the T-cell when the CAR-T binds its target. Second and third generation CAR-Ts have additional costimulatory domains that further enhance the immune response.
The most common procedure for CAR-T therapy consists in the extraction of T-cells from the own patient, which are then genetically modified and expanded in vitro. Finally, they are reinfused into the patient ready to fight the tumor.
Checkpoint inhibitors have already been incredibly successful. The drugs inhibitthe mechanism that tumor cells use to inhibit T-cell activity and overcome the immune system. CAR-T goes one step further and engineers the T-cell itself to enhance the immune response against a specific tumor antigen.
CAR-T clinical trials have shown huge remission rates, of up to 94% in severe forms of cancer, which is particularly impressive considering most of the trials recruit patients that have not responded to all other available treatments for their form of cancer.These preliminary results have fed the expectations of patients and investors alike, but its important to remember that the therapy also has flaws.
Im just trying to be realistic, CAR-T is not the miracle cure for cancer, Andr Choulika, CEO of Cellectis,told us.CAR-T therapy has in fact been linked tosevere side-effects, such as neurotoxicity and cytokine release syndrome.The recent report of several deaths in CAR-T trials made many realize that the technology might not be as perfect as many had originally expected.
These results mostly come from the most studied application of CAR-T, which targets the CD19 antigen found in B-cells.The companies leading the development of CAR-T all target the CD19 antigen to treat B-cell malignancies, which include several forms of lymphoma and leukemia.
The initial furor and excitement of CAR-T hasled to extensive and rapid clinical development in the CD19 target space, saysDavid Gilham, R&D VP at Celyad. Research is busy catching up at the moment, in particular concerning toxicity. The lack of good preclinical models hampers this work, but with clinical samples available, ongoing investigations are now closer to identifying the underlying mechanisms and further refining the approach.
There are several companies competingto be the first tomarket. Competition is tight and the results of a clinical trial can change everything.Juno Therapeutics, whichused to lead the race has just announced the termination of its lead CAR-T program after a total of 5 patients died of cerebral edema caused by the therapy. The company had created huge expectations, and itmarket cap reached over 2.5Bn only 3 years after its inception.
In terms of clinical development, Novartis seems to be leading now. In November, the company recently presented results from a Phase II trial with its CAR-T candidate CTL019 for B-cell acute lymphoblastic leukemia (ALL), which achieved remission in 82% of patients after 3 months. The company is preparing to submit applications to the FDA and EMA this year, despite 50% of patients in the trial were reported to present severe side-effects.
Kite Pharmajustreportedresults from a Phase II clinical trial with its lead candidate, axicabtageneciloleucel, previously KTE-C19. The therapy managed to keep 36% of patients with lymphoma clear of the disease after 6months, which made Kites shares jump by 16%. However, this ongoing trial has already reported three deaths, two of them linked to the CAR-T therapy.Hoping to get ahead of Novartis, Kite Pharmastarted regulatory submissions with the FDAin December.
Despitesevere side-effects and several deaths in clinical trials, some argue that CAR-T therapy is worth the risk when a patient has not responded to any other available treatments. But others are already developing improved versions of CAR-T that are safer for the patients.
Cellectis originally developed UCART19, now licensed to Servier and Pfizer. Its a CAR-T therapy with a switch control system that only activates the engineered cells when rapamycin is present. The therapy is in Phase I and has already saved two babies with aggressive forms of leukemia. Bellicum Pharmaceuticals, in the US, is developing a similar technologycalled GoCAR-T that requiresrimiducid for CAR-T cell activation.
For its part, Celyad is developing a version of CAR-T that makes T-cells express Natural Killer Receptors (NKRs).Its disruptive because NKR-2 binds to 8 different ligands that are expressed on above 80% of solid and hematological malignancies, said Christian Homsy, CEO and co-founder of Celyad.Weve started one of the largest and broadesttrials in the sector, targeting 7 indications.
Targeting solid tumors is a big challenge in the field of immuno-oncology. Low T-cell infiltration and an immunosuppressive environment prevent the immune system from effectively attacking solid tumors. Bluebird bio and Celgene are developing their own CAR-T technology for solid tumors from the US.
Others think that the way to go for CAR-T is combination therapies. We are excited about combining checkpoint inhibitors such as PD-1 inhibitors and anti-CTLA4 drugs with CAR-T cells, said Zelig Eshhar, pioneer of the CAR-T technology at the NIH, for The Scientist.
Most approaches to CAR-T engineer the patients own cells, but this process requires several weeks and is expensive. Some estimates for the therapys price go over 500,000. A possible solution is allogeneic CAR-T therapy, i.e. sourced from a healthy donor and ready to go when the patient needs it.
Cellectis and Celyad are developing their ownallogeneic CAR-T each, and theres friction between them both. In this area, Celyad is still in preclinical phase, while Cellectis UCART123 recently received FDA approval to start clinical trials, making it the first study for allogeneic CAR-T in humans.
The technology promises a faster and cheaper approach to CAR-T, but developing an off-the-shelf therapyis a scientifically challenging avenue according to Celyads CEOChristian Homsy.
I doubt that allogeneic CAR-T can be a real off-the-shelf therapy, he commented. There are still some significant scientific challengeswith regards to immunology, as well as manufacturing, transportation, traceability and banking solutions necessary to reach the scale needed for widespread patient treatment.
As you can appreciate, theres plenty going on in the CAR-T space. The technology is not perfect yet, but it offers hope for patients that had none before. Whoever makes it first to the market will open the way for better alternatives to come in the next years.
Images from CI Photos /Shutterstock; Kite Pharma;Klebanoff et al. (2014) Nature Reviews Clinical Oncology 11, 685686;Bellicum Pharmaceuticals
Go here to read the rest:
A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology - Labiotech.eu (blog)
Posted in Cell Therapy
Comments Off on A Cure for Cancer? How CAR-T Therapy is Revolutionizing Oncology – Labiotech.eu (blog)
Hospital group invests $20M in stem cell therapy biotech – FierceBiotech
Posted: March 7, 2017 at 8:44 am
Hospital group Sanford Health has invested $20 million in InGeneron to support clinical trials of a stem cell regenerative medicine. The Series D gives Sanford a financial stake in an adipose-derived stem cell therapy it is testing in a clinical trial at its network of healthcare facilities.
InGeneron began working with Sanford on an 18-person trial of its stem cell injection in patients with partial thickness rotator cuff tears around the turn of the year. And the network of 45 hospitals and close to 300 clinics has now tightened its ties to InGeneron by investing $20 million in the Houston, TX-based regenerative medicine company. InGeneron sees benefits in strengthening its relationship with Sanford.
This significant investment demonstrates Sanfords commitment to be an active participant in InGeneron as well as being our clinical trial site of choice. Our joint efforts will enable the company to make regenerative cell therapies available to clinical practice and to establish a leading position in the application of adipose-derived regenerative cells, InGeneron President Ron Stubbers said in a statement.
Sanford runs the two trial sites that are enrolling patients in the aforementioned 18-person trial. Both sites specialize in orthopedics and sports medicine. Rotator cuff injuries are associated with overhead sports, such as baseball and tennis. The healthcare system is presenting its close involvement with InGeneron as a positive for the patients it serves because it facilitates early access to an experimental therapy.
The treatment entails processing adipose tissue harvested during liposuction to create a mixture containing stem cells and nutrients. This mixture is injected into the site of the injury. In the trial, one-third of participants will form a control arm and receive a cortisone injection instead of stem cells.
The exec team tells FierceBiotech that the first patients were enrolled in the feasibility trial for rotator cuff tendinopathy in January, with U.S. regulatory market approval "anticipated in 2020."
InGeneron last raised money last year through a $4.5 million seed round. That financing, which came 10 years after InGeneron was founded, followed studies of the companys cell therapies in knee surgeries. InGeneron also makes biomedical equipment for collecting and processing adipose tissue.
The biotech has and its subsidiaries on both sides of the Atlantic has a team of 30 people, and has raised $38 million to date.
Excerpt from:
Hospital group invests $20M in stem cell therapy biotech - FierceBiotech
Posted in Cell Therapy
Comments Off on Hospital group invests $20M in stem cell therapy biotech – FierceBiotech
Stem Cell Therapy An Option For ENC Patients | Public Radio East – Public Radio East
Posted: March 7, 2017 at 8:44 am
Stem cell therapy is a quickly advancing treatment being used across the country. Now, its becoming more prevalent in eastern North Carolina to those living with chronic pain an alternative to surgery. The minimally invasive procedure is showing results in alleviating back, knee, hip and shoulder pain. Though stem cell therapy is classified by the Food and Drug Administration as experimental, patients say theyre finding relief. Meet New Bern resident and a local endodontist Dr. Donnie Luper. He was skeptical of the procedure at first.
How did you know what those stem cells were going to differentiate into? I mean was I going to grow a foot out of my shoulder or something like that?
Luper tore his rotator cuff 25 years ago during a tubing incident on the Trent River. A subsequent fall during a golf trip in 2015 sent him to a specialist.
I went to see a shoulder surgeon in Richmond. He told me that he didnt think it was a complete tear of my rotator cuff, that I could probably have a minor surgical procedure done and I asked him about stem cell.
After talking with a friend who opted for stem cell treatment for her knee pain, Luper decided to find out more.
My option was if I would have had that shoulder surgery and they had do that bicep tendon repair, I mean I would have been in a sling for six weeks and probably not working for three months.
According to the Food and Drug Administration, stem cells sometimes called the bodys master cells - have the ability to divide and develop into many different cell types. Each new cell has the potential to remain a stem cell or become another type of cell, such as a nerve cell, a skin cell, or a red blood cell. They may also help repair the body by dividing to replenish cells that are damaged by disease, injury or normal wear. Parkinsons disease, spinal cord injuries, damaged organs and cancer could all be possibly treated with the use of stem cells, but more research is needed. Dr. Angelo Tellis is the owner/physician of Aegean Medical, which provides stem cell therapy to patients in Cary, Jacksonville, Morehead City and New Bern.
The adult stem cells we call multipotent stem cells so they can only differentiate into very specific or certain kinds of tissue. Whereas the embryonic stem cells we call pluripotent and can become a variety, almost any tissue. But I only deal with adult stem cells, theyre found to be more useful in clinical applications.
Dr. Tellis says adult stem cells are more responsive to growing tissue in very specific locations. When patients go into Dr. Tellis office for the two hour procedure, he starts by numbing an area of the abdomen and performing liposuction to collect one or two syringes of body fat.
Stem cells can be found in a lot of different tissues throughout the body, but theyre actually in one of the highest concentrations in your own body fat.
The stem cell sample is combined with platelet rich plasma or PRP collected through a blood draw.
That has a lot of the chemical signals and messengers that activate stem cells. So Ill typically combine that with some of the stem cells collected from the body fat and then go under x-ray guidance and put it exactly in the targeted location where we want to create that healing process.
Soreness and stiffness can be expected immediately following the procedure and for about a week after. Dr. Tellis says the results tend to improve with time, taking about three to six months for full recovery. This was Lupers experience in 2016.
Really didnt have to take any pain medications. The joint was really sore over the weekend just because of the injection of the fluid there and after that, I had a small amount of discomfort, but nothing I really had to take medication for.
After three months, Luper says he felt 90 percent better. But he decided to get a second opinion from a shoulder surgeon.
And he told me he thought the stem cells had done a lot but that I still had one little bone spur that was rubbing against the muscle and constantly tearing the little bit of the muscle.
After surgery, Luper says his left shoulder started feeling significantly better in about a month. He was also able to return to one of his favorite pastimes golf. While surgery helped eliminate all of his pain, Luper believes stem cells helped regenerate tissue that was damaged years ago.
He said my rotator cuff muscle didnt even look like it had been torn. I actually tore that, Im sixty now, and I actually tore that when I was 34, 35 tubing on the river and I had to do physical therapy for about three months, but he said he saw absolutely no evidence that Id ever had a rotator cuff tear.
Even though some have found relief and possibly a cure through stem cell therapy, the Food and Drug Administration has not approved any stem cell-based products for use, other than HEMACORD (HE-muh-cord). According to their website, the use of stem cells raises safety concerns such as excessive cell growth, the development of tumors as well as cells migrating from the site of administration and differentiating into inappropriate cell types. And then, theres the cost of the procedure, which is not covered by insurance. The price for the treatment ranges from $2,500 to $5,000. But for those who want to avoid major surgery and the downtime associated with recovery, the risk and cost may be worth it.
If Id have surgery, my deductible would have been that because I have an out-of-pocket max. And I would want to do anything to avoid surgery, especially something that would keep me out of work for three months.
The FDA recommends that consumers interested in stem cell therapy should start a conversation with their doctor about the potential risk to benefit ratio. In addition to Aegean Medical, Advanced Health and Physical Medicine in Greenville and Regenerative Medicine Clinic of Wilmington also provide stem cell therapy in eastern North Carolina.
The rest is here:
Stem Cell Therapy An Option For ENC Patients | Public Radio East - Public Radio East
Posted in Cell Therapy
Comments Off on Stem Cell Therapy An Option For ENC Patients | Public Radio East – Public Radio East
Northern Colorado Doctor Kenneth Pettine Releases Information on Mesenchymal Stem Cell Therapy for Chronic Neck … – Benzinga
Posted: March 7, 2017 at 8:44 am
Dr. Kenneth Pettine, a board certified retired Orthopedic Surgeon and one of the Top 50 Spine Surgeons and Specialist to Know according to Becker's Spine Review, is offering to educate the public about mesenchymal stem cell therapy in Northern Colorado. Mesenchymal stem cells are being studied by Dr. Pettine for their ability to treat orthopedic conditions such as osteoarthritis and other joint and disc related chronic neck and back pain.
(PRWEB) March 07, 2017
Dr. Kenneth Pettine, a Northern Colorado board-certified retired orthopedic surgeon, is currently researching the use of the mesenchymal stem cell and their potential in treating orthopedic conditions such as osteoarthritis or other joint and disc related issues. He's now releasing more information about what these incredible stem cells are and the exciting therapeutic opportunities of mesenchymal stem cell therapy for the interested public in Northern Colorado.
Stem cells are rare, unique cells in our body that can duplicate themselves over and over again and can continue to regenerate throughout our lives. Each particular stem cell can only become either one type or a very limited number of cell types. As we get older, we have fewer stem cells in our body, which is why we have a decreased ability to heal and avoid diseases like cancer. Introducing new stem cells to the body could help counteract the effects of degenerated joints and chronic neck and back pain.
Mesenchymal stem cell are one type of stem cell, and the one that Dr. Pettine is using to focus his clinical research on stem cell therapy. This particular type of stem cell modulates your immune system, is extremely anti-inflammatory and has many positive effects in helping your body treat autoimmune conditions. The mesenchymal stem cell is the main cell helping your body heal from orthopedic and spine injuries and helping treat degenerative conditions such as arthritis.
Almost all of this research involves mesenchymal stem cells obtained from bone marrow. Most all these studies involved obtaining the mesenchymal stem cell from a donor's bone marrow and then expanding these cells in a laboratory. The number of mesenchymal stem cells in a petri dish can be increased to result in several hundred million cells. These cells are then put into recipient animals and humans to study their ability to treat numerous autoimmune diseases such as Parkinson's, multiple sclerosis, crohn's disease, asthma, lupus, to name just a few. These cells are also being studied to treat and regrow damaged heart muscle after a heart attack. Extensive research is being conducted to evaluate the safety and efficacy of utilizing mesenchymal stem cells to treat orthopedic conditions such as osteoarthritis of your joints and disc related chronic back and neck pain.
This has exciting implications for chronic neck and back pain sufferers. These Mesenchymal stem cells could help regenerate tissue in the spine, reversing issues like degenerative disc disease. The stem cells could also decrease pain-causing inflammation and help patients recover from accidents and injuries faster.
If you are a chronic neck or back pain sufferer and would like to learn more about Dr. Pettine's research on Mesenchymal stem cell therapy, visit his website at http://www.KennethPettine.com for more information.
About Dr. Kenneth Pettine Dr. Pettine is currently the principal investigator for 18 FDA studies evaluating non-fusion spine surgery implants and stem cells for their uses in treating spine pathology. He is considered a pioneer in the field of biologics to treat orthopedic and spine pathology. He founded The Rocky Mountain Associates in Orthopedic Medicine in 1991 to offer patients a non-fusion surgical option for their neck and back pain. He co-invented the FDA-approved Prestige cervical artificial disc and the Maverick Artificial Disc. He is currently focused on educating anyone interested in learning about the use of Mesenchymal stem cell therapy. You can learn more about stem cells and Dr. Pettine at his website, http://www.KennethPettine.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/03/prweb14124517.htm
Here is the original post:
Northern Colorado Doctor Kenneth Pettine Releases Information on Mesenchymal Stem Cell Therapy for Chronic Neck ... - Benzinga
Posted in Cell Therapy
Comments Off on Northern Colorado Doctor Kenneth Pettine Releases Information on Mesenchymal Stem Cell Therapy for Chronic Neck … – Benzinga
Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress
Posted: March 5, 2017 at 9:41 am
LONDON Technavio analysts forecast the global stem cell therapy market to grow at a compound annual growth rate of close to 37 percent during the forecast period, according to their latest report.
The research study covers the present scenario and growth prospects of the global stem cell therapy market for 2017-2021. To determine the market size, the study considers revenue generated from allogenic and autogenic stem cell therapies.
The Americas are the largest regional segment of the global stem cell therapy market, responsible for generating over 56 percent of the total revenue (2016 figures). The region is expected to continue market dominance through the forecast period, driven by increasing demand for stem cell therapy products and investments into R&D.
Technavio analysts highlight the following factors as contributing to the growth of the global stem cell therapy market:
Increase in federal funding in stem cell therapy.
Sapna Jha, one of the lead research analysts at Technavio for medical imaging research, says, Many stem cell research institutes and small companies are involved in cutting-edge R&D and are yielding encouraging results. These institutions are witnessing an increased flow of investments from federal organizations, due to the realization of the importance of regenerative medicine.
The U.S. National Institutes of Health, a major funding government organization invested approximately USD 1.5 billion in stem cell research projects in 2016. Similarly, several state-level organizations such as California Institute for Regenerative Medicine has contributed USD 3 billion to stem cell research in 2014. Such funding will help various research institutes to discover and develop regenerative medicines, which will boost the global regenerative medicine market enormously.
Growing demand for personalized medicine.
The health care sector is creating a high demand for personalized medicine, which could offer game-changing opportunities for the vendors. These medicines offer treatments based on the individual characteristics, needs, and preferences, which will vastly improve the quality of health care. Individuals are increasingly banking their stem cells for future treatments. Research organizations are also extensively exploring ways to develop personalized treatments with stem cells, which could eventually erase the conventional medicine system and help in the effective treatment of various diseases such as diabetes and cancer.
Demand for development of effective drugs for cardiology and degenerative disorders.
There has been an increased demand to develop effective drugs for cardiology and degenerative disorders, for which there were no effective treatment plans before the advent of stem therapies. The discovery of possible cardiac stem cells uncovered new arenas to repair hearts injured due to acute myocardial infarction or coronary artery disease, says Sapna.
Researchers are studying and developing approximately 19 product candidates for the treatment of cardiac disorders, with eight of them in Phase III, and six in Phase II.
Technavio is a global technology research and advisory company. This report was made available through The Associated Press.
Visit link:
Opinion/Commentary: Global stem cell therapy market to showcase growth - The Daily Progress
Posted in Cell Therapy
Comments Off on Opinion/Commentary: Global stem cell therapy market to showcase growth – The Daily Progress
Teenager’s sickle cell reversed with world-first therapy – BBC News
Posted: March 3, 2017 at 10:41 am
Fox News | Teenager's sickle cell reversed with world-first therapy BBC News A French teenager's sickle cell disease has been reversed using a pioneering treatment to change his DNA. The world-first procedure at Necker Children's Hospital in Paris offers hope to millions of people with the blood disorder. Scientists altered the ... Doctors reverse teen's sickle cell disease with innovative gene therapy Gene therapy shows early promise against sickle cell Game-Changing Gene Therapy Nullifies Patient's Sickle Cell Disease |
See original here:
Teenager's sickle cell reversed with world-first therapy - BBC News
Posted in Cell Therapy
Comments Off on Teenager’s sickle cell reversed with world-first therapy – BBC News
Keithley’s Korner: Big benefits from Stem Cell Therapy – Ruidoso News
Posted: March 3, 2017 at 10:41 am
Tim Keithley, Guest columnist 7:45 a.m. MT March 2, 2017
Tim Keithley(Photo: Courtesy)
Like a lot of folks who love to go skiing, play tennis, and enjoy the Ruidoso year-round beautiful weather, I became discouraged when my right knee went out climbing down a staircase recently.
I waited a few days figuring that it might heal like it always has done before. But this time the injury felt different and seemed to be getting worse.
Turns out you have a torn tendon in your right knee, Dr. Steven Rath of Fusion Medical Spa said on New Mexico in the Morning.
It obviously wasnt going to heal itself, so we had Tim come in and consider stem cell therapy, Dr. Rath said. It turns out that we were able to help his body heal itself without putting him through painful knee surgery.
Within a day after the procedure this week, the knee was sore from having the shots injected right into the tendon, but the regular pain had subsided. It made me a believer in the stem cell therapy Dr. Rath has been talking about on the radio for some time.
Heres a simple explanation of the procedure: Dr. Rath draws your own blood, then separates out the healing platelets through a spinning process, then injects those back into your body to the specific area that needs healing.
Stem cell therapy is nothing new, but its still considered an alternative form of treatment and an experiment, Dr. Rath said. Part of the reason why insurance companies dont cover the procedure has to do with the fact that medical companies prefer patients have surgery when it may not be necessary.
There may be patients out there who definitely need surgery, but providing this procedure has kept many of my patients from having to go under the knife.
Having had the procedure done on my knee this week, I can testify that it works and has given me a new hope that soon Ill be back on the slopes and the tennis court without having the ordeal of potential knee surgery.
Thus far in my practice, stem cell therapy has helped many people in your same situation, Dr. Rath said.
Tim Keithley is the host of the New Mexico in the Morning radio show Monday through Friday, 9 to 10 a.m., on KRUI 1490 AM, KWMW 105.1 FM and 99.1 FM or live streaming at mtdradio.com.
Read or Share this story: http://r-news.co/2lDmO8k
Continue reading here:
Keithley's Korner: Big benefits from Stem Cell Therapy - Ruidoso News
Posted in Cell Therapy
Comments Off on Keithley’s Korner: Big benefits from Stem Cell Therapy – Ruidoso News
Journey of hope: City native seeks stem cell therapy to heal Bristol … – Bristol Observer (registration)
Posted: March 3, 2017 at 10:41 am
By LISA CAPOBIANCO
STAFF WRITER
When Bristol native Kevin Ouellette was born without an esophagus over 40 years ago, he made medical history.
While only a couple of hours old, Ouellette underwent a surgery that took part of his large intestine and connected it to where he was missing the esophagusand survived.
Hes the only one who survived that surgery, said Ouellettes mother, Sharon Viel of Bristol.
Post-surgery, Ouellette led a normal life, enjoying hobbies like cooking and fishing.
He married his wife, Janice, in 1992 and had two children, Albert and Jenna. Together they enjoyed various family outings like camping and going on Sunday drives.
But life suddenly changed in an instant when at age 32, Ouellette had a massive heart attack, leading him to undergo triple bypass surgery and months of recuperation.
Since then, Ouellette had two more heart attacks, in addition to battling aspiration pneumonia a couple dozen times and countless hospital stays.
He then hit rock bottom after having a fifth heart attack.
It wasnt until I had the last heart attack that it went down hill pretty bad, said Ouellette, who had to retire from his job as a production manager for a manufacturing company.
Due to the heart attacks and aspiration pneumonias, along with other health issues, Ouellettes heart is permanently damaged, and now functions at 25 percent. In addition, his lungs now function at 16 percent.
I didnt have any breathing apparatuses four months ago, said Ouellette, who was diagnosed with COPD.
His heartnow functions at 25 percent, so its not pushing oxygen through his lungs, said Janice. Thats a big part of the breathing issues.
Although his pulmonologist suggested a heart/lung transplant, Ouellette found out from his thoracic surgeon that the transplant would involve removing his esophagusa type of surgery that has never been performed.
But the Ouellette family never lost hope. Ouellette hopes to receive stem cell therapy to improve his lung function.
After conducting research to find a reputable stem cell therapy center, the Ouellette family came across one in New York City that seems to be promising: Park Avenue Stem Cell Therapy Center.
Founded in 2015, Park Avenue Stem Cell Therapy Center has two board-certified surgeons with over 30 years of medical experience and treats a variety of diseasesfrom
cardiac/pulmonary to autoimmune to urologic.
The family recently visited the center, which uses fat derived stem cells for deployment and clinical research. According to Park Avenues website, autologous stem cells from a patients own fat are simple to harvest safely under local anesthesia and are abundant in quantities up to 2,500 times those seen in bone marrow. Once the fat derived stem cells are administered back into the patient, they have the potential to repair human tissue by forming new cells of mesenchymal origin, including cartilage, bone, ligaments, tendons, nerve, fat, muscle, blood vessels, and certain internal organs, Park Avenues website further explains.
Although stem cell therapy has not yet been approved by the FDA, Ouellette and his family still have faith that this could be the treatment that will heal his lungs.
Its still experimental, said Ouellette. Butmy surgery was experimental when I was a child. Very few children lived through my surgery.
Weve searched over the years to find someone his age that lived for as long as he has, and we have yet to find anybody with other medical problems. His thoracic surgeon in Boston travels all over the place, and he has yet to find somebody that was born like that and has other complications, and is still alive at this age, said Janice.
We have a glimmer of hope, added Sharon.
If all goes according to plan, Ouellette hopes to undergo the therapy by the end of the month or in April. As the procedure is not covered by insurance, Jenna and Albert recently set up a GoFundMe page for their father, whom they also refer to as their Superman. To date, the online fundraiser has received over $2,000 in donations. The family also is planning a pasta dinner this Sunday (March 5) at the Bristol Polish Club.
Its an ongoing costly [treatment]. Hell still need treatments after every three months for the first year, said Janice. Weve done a lot of research, and found a lot of patients who have undergone it. We read their thoughts, and it was positive, so we can only hope that it works.
Although the Ouellette familys daily lives have changed, their love and support for one another have remained the same inside their Terryville home. One addition to the family that has brightened their day is Ouellettes six-month-old granddaughter, Sofiathe daughter of Albert and his girlfriend, Emily Kuharski.
We have a huge support system, said Janice, adding how her family has received an outpour of support from the community.
Always stay positiveno matter how bad the situation looks, said Albert.
The pasta dinner benefit for Kevin Ouellette will take place on Sunday (March 5), 1 p.m. to 5 p.m. at the Bristol Polish Club, 541 North Main St., Bristol. Tickets are available at the door for $15 per adult and $5 per child.
To make a donation, visit http://www.gofundme.com/ stemcellsforsuperman.
The Ouellette family of Terryville is hosting a pasta dinner benefit for their Superman, Kevin Ouellette, second to the left, this Sunday. Kevin has an opportunity to undergo a therapy that will improve his lung function. (SUBMITTED)
Posted in Cell Therapy
Comments Off on Journey of hope: City native seeks stem cell therapy to heal Bristol … – Bristol Observer (registration)
Kite’s CAR T-Cell Therapy Success – The Scientist
Posted: March 1, 2017 at 11:41 pm
The Scientist | Kite's CAR T-Cell Therapy Success The Scientist Last year, both Juno Therapeutics and Kite Pharma announced that a small number of patients had died in their respective CAR T-cell therapy trials. Juno's trial was halted, but Kite's carried on. The Kite study enrolled 77 patients with advanced ... CAR T-cell therapy turns blood cells into cancer fighters Gene therapy "seems extraordinary" at fighting blood cancer in study, experts say Terminal cancer patients in complete remission after one gene therapy treatment |
Read more from the original source:
Kite's CAR T-Cell Therapy Success - The Scientist
Posted in Cell Therapy
Comments Off on Kite’s CAR T-Cell Therapy Success – The Scientist
Stem Cell Therapy Market Worth 145.8 Million USD by 2021 – Yahoo Finance
Posted: March 1, 2017 at 11:41 pm
PUNE, India, February 28, 2017 /PRNewswire/ --
According to a new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021" published by MarketsandMarkets, the market is expected to reach USD 145.8 Million by 2021, growing at a CAGR of 11.0%.
(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )
Browse 60 market data Tables and 37 Figures spread through 120 Pages and in-depth TOC on "Stem Cell Therapy Market"
http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html
Early buyers will receive 10% customization on this report.
The report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW) for the forecast period of 2016 to 2021. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global Stem Cell Therapy Market.
On the basis of type, the global Stem Cell Therapy Market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share in the global Stem Cell Therapy Market in 2016. This large share can primarily be attributed to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials related to allogeneic stem cell therapies.
Inquiry Details: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48
On the basis of therapeutic application, the global Stem Cell Therapy Market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of the global Stem Cell Therapy Market in 2016. This large share can be attributed to the rising availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases, and growing patient preference for effective & early treatment strategies.
North America is expected to be the largest regional segment in the global Stem Cell Therapy Market in 2016, followed by Asia-Pacific. In addition, the North American Stem Cell Therapy Market is expected to be the fastest growing region during the forecast period. Factors such as growing awareness related to the therapeutic potency of stem cells, increasing number of clinical trials for stem cell-based products, and increasing public-private funding & research grants are driving the growth of this market.
Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=48
As of 2015, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) are some of the key players operating in the global Stem Cell Therapy Market.
Browse Related Reports:
Stem Cell Assay Market by Type (Viability, Differentiation, Cell Identification), Kit (Mesenchymal, IPSCS, Hematopoietic), Product (Flow Cytometer, Detection Kit), Application (Regenerative Medicines, Drug Development), End User - Forecast to 2021
http://www.marketsandmarkets.com/Market-Reports/stem-cell-assay-market-47610330.html
Stem Cell Banking Market by Bank Type (Cord Blood, and Cord Tissue), Service (Collection & Transportation, Analysis, Processing, and Storage), Application (Cerebral Palsy, Leukemia, Thalassemia, Anemia, Autism, Diabetes), Region - Forecast to 2021
Read More
http://www.marketsandmarkets.com/Market-Reports/stem-cell-banking-market-220680183.html
About MarketsandMarkets:
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Contact: Mr. Rohan MarketsandMarkets 701 Pike Street Suite 2175, Seattle, WA 98101, United States 1-888-600-6441 Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @http://www.linkedin.com/company/marketsandmarkets
Original post:
Stem Cell Therapy Market Worth 145.8 Million USD by 2021 - Yahoo Finance
Posted in Cell Therapy
Comments Off on Stem Cell Therapy Market Worth 145.8 Million USD by 2021 – Yahoo Finance